THE PROMISE AND CHALLENGE OF THERAPEUTIC GENOME EDITING

Genome editing, which involves the precise manipulation of cellular DNA sequences to alter cell fates and organism traits, has the potential to both improve our understanding of human genetics and cure genetic disease. Here I discuss the scientific, technical and ethical aspects of using CRISPR (clustered regularly interspaced short palindromic repeats) technology for therapeutic applications in humans, focusing on specific examples that highlight both opportunities and challenges. Genome editing is—or will soon be—in the clinic for several diseases, with more applications under development. The rapid pace of the field demands active efforts to ensure that this breakthrough technology is used responsibly to treat, cure and prevent genetic disease. The scientific, technical and ethical aspects of using CRISPR technology for therapeutic applications in humans are discussed, highlighting both opportunities and challenges of this technology to treat, cure and prevent genetic disease.

[1]  Y. Suh,et al.  In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease , 2017, F1000Research.

[2]  Sung Tae Kim,et al.  Gold nanoparticles for nucleic acid delivery. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Freeman Lan,et al.  Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair , 2017, Nature Biomedical Engineering.

[4]  Steven Lin,et al.  Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery , 2014, eLife.

[5]  Ivan Merelli,et al.  Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response , 2019, Cell stem cell.

[6]  Hunter B. Fraser,et al.  Functional Genetic Variants Revealed by Massively Parallel Precise Genome Editing , 2018, Cell.

[7]  Martin J. Aryee,et al.  Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors , 2019, Nature.

[8]  Sruthi Mantri,et al.  CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells , 2016, Nature.

[9]  Daesik Kim,et al.  Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases. , 2019, Annual review of biochemistry.

[10]  L. Tran,et al.  The CRISPR/Cas9 system and its applications in crop genome editing , 2019, Critical reviews in biotechnology.

[11]  Qiaobing Xu,et al.  Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents , 2017, Nature.

[12]  Sruthi Mantri,et al.  Identification of preexisting adaptive immunity to Cas9 proteins in humans , 2018, Nature Medicine.

[13]  Haiyan Jiang,et al.  Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population , 2018, Molecular therapy. Methods & clinical development.

[14]  Chunyan Ren,et al.  Highly efficient therapeutic gene editing of human hematopoietic stem cells , 2019, Nature Medicine.

[15]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[16]  R. David Hawkins,et al.  Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy , 2017, Nature Communications.

[17]  Philip J. Santangelo,et al.  High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing , 2018, Proceedings of the National Academy of Sciences.

[18]  F. Gleason,et al.  Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA , 2014 .

[19]  R. Barrangou,et al.  Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria , 2012, Proceedings of the National Academy of Sciences.

[20]  Haiyan Jiang,et al.  Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10 , 2019, Nature Medicine.

[21]  David R. Liu,et al.  Search-and-replace genome editing without double-strand breaks or donor DNA , 2019, Nature.

[22]  Y. Doyon,et al.  In vivo genome editing of the albumin locus as a platform for protein replacement therapy. , 2015, Blood.

[23]  Kira S. Makarova,et al.  Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL domain-containing accessory protein , 2018, Molecular cell.

[24]  Ross C Wilson,et al.  The Daunting Economics of Therapeutic Genome Editing. , 2019, The CRISPR journal.

[25]  Jennifer A. Doudna,et al.  CRISPR-Cas guides the future of genetic engineering , 2018, Science.

[26]  Max A. Horlbeck,et al.  Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation , 2014, Cell.

[27]  James N. Hughes,et al.  Inter-homologue repair in fertilized human eggs? , 2008, Nature.

[28]  D. Boffelli,et al.  CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells , 2018, bioRxiv.

[29]  Y. K. Kim,et al.  Efficient intracellular delivery of biomacromolecules employing clusters of zinc oxide nanowires. , 2017, Nanoscale.

[30]  Jennifer A. Doudna,et al.  Generation of knock-in primary human T cells using Cas9 ribonucleoproteins , 2015, Proceedings of the National Academy of Sciences.

[31]  Rachid Benchaouir,et al.  AAV Production Using Baculovirus Expression Vector System. , 2019, Methods in molecular biology.

[32]  Ying Sun,et al.  CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes , 2015, Protein & Cell.

[33]  F. Manfredsson,et al.  Multimodal Production of Adeno-Associated Virus. , 2019, Methods in molecular biology.

[34]  Mengmeng Gong,et al.  CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein , 2017, Molecular Genetics and Genomics.

[35]  Fulvio Mavilio,et al.  Gene therapy , 1993, Nature.

[36]  Seung Woo Cho,et al.  Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease , 2013, Nature Biotechnology.

[37]  Yonatan Stelzer,et al.  Editing DNA Methylation in the Mammalian Genome , 2016, Cell.

[38]  W. Harrington,et al.  A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. , 2018, Cell reports.

[39]  Michael L Kaufman,et al.  Improving Gene Editing Outcomes in Human Hematopoietic Stem and Progenitor Cells by Temporal Control of DNA Repair , 2018, Stem cells.

[40]  Robert Langer,et al.  Delivery technologies for cancer immunotherapy , 2019, Nature Reviews Drug Discovery.

[41]  Mingfeng Qiu,et al.  Advances of blood cell‐based drug delivery systems , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[42]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[43]  Daesik Kim,et al.  Genome editing reveals a role for OCT4 in human embryogenesis , 2017, Nature.

[44]  L. Pauling,et al.  Sickle cell anemia a molecular disease. , 1949, Science.

[45]  Hui Li,et al.  Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy , 2017, Science Translational Medicine.

[46]  Joana A. Vidigal,et al.  In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system , 2014, Nature.

[47]  V. Ingram,et al.  Gene Mutations in Human Hæmoglobin: the Chemical Difference Between Normal and Sickle Cell Hæmoglobin , 1957, Nature.

[48]  Michael L Kaufman,et al.  Reactivating Fetal Hemoglobin Expression in Human Adult Erythroblasts Through BCL11A Knockdown Using Targeted Endonucleases , 2016, Molecular therapy. Nucleic acids.

[49]  Andreas Reinisch,et al.  Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6 , 2017, eLife.

[50]  A. Kondo,et al.  Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems , 2016, Science.

[51]  Jennifer Doudna,et al.  RNA-programmed genome editing in human cells , 2013, eLife.

[52]  David R. Liu,et al.  In vivo base editing of post-mitotic sensory cells , 2018, Nature Communications.

[53]  Jing-Zhang Wang,et al.  The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD , 2017, Brain and Development.

[54]  H. Fraser,et al.  Functional genetic variants revealed by massively parallel precise genome editing. Sharon et al , 2018 .

[55]  Irene Georgakoudi,et al.  Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles , 2016, Proceedings of the National Academy of Sciences.

[56]  Dongsheng Duan,et al.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy , 2016, Science.

[57]  Jack W. Szostak,et al.  The double-strand-break repair model for recombination , 1983, Cell.

[58]  Hui Yang,et al.  Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis , 2019, Nature.

[59]  Adrian Pickar-Oliver,et al.  The next generation of CRISPR–Cas technologies and applications , 2019, Nature Reviews Molecular Cell Biology.

[60]  Nevan J Krogan,et al.  A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells. , 2016, Cell reports.

[61]  L. Steinmetz,et al.  Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos , 2019, Science.

[62]  K. Quinlan,et al.  A natural regulatory mutation in the proximal promoter elevates fetal globin expression by creating a de novo GATA1 site. , 2019, Blood.

[63]  Adrian J. Thrasher,et al.  Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells , 2017, Science Translational Medicine.

[64]  George M. Church,et al.  In vivo gene editing in dystrophic mouse muscle and muscle stem cells , 2016, Science.

[65]  David R. Liu,et al.  Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage , 2016, Nature.

[66]  Jeremy M. Stark,et al.  Genetic Steps of Mammalian Homologous Repair with Distinct Mutagenic Consequences , 2004, Molecular and Cellular Biology.

[67]  M. Porteus,et al.  A New Class of Medicines through DNA Editing , 2019, The New England journal of medicine.

[68]  M. Hirata,et al.  Generation of a TP53-modified porcine cancer model by CRISPR/Cas9-mediated gene modification in porcine zygotes via electroporation , 2018, PloS one.

[69]  Kevin S. Smith,et al.  MLL leukemia induction by genome editing of human CD34+ hematopoietic cells. , 2015, Blood.

[70]  Benjamin L. Oakes,et al.  CRISPR-CasX is an RNA-dominated enzyme active for human genome editing , 2019, Nature.

[71]  R. Barrangou,et al.  Characterization and Repurposing of Type I and Type II CRISPR-Cas Systems in Bacteria. , 2019, Journal of molecular biology.

[72]  Jianhui Gong,et al.  Correction of a pathogenic gene mutation in human embryos , 2018, Yearbook of Paediatric Endocrinology.

[73]  Brian K. Kaspar,et al.  Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[74]  Petra Reinke,et al.  High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population , 2018, Nature Medicine.

[75]  Yang Yang,et al.  A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice , 2016, Nature Biotechnology.

[76]  Christina Mayer,et al.  Standardized, Scalable, and Timely Flexible Adeno-Associated Virus Vector Production Using Frozen High-Density HEK-293 Cell Stocks and CELLdiscs , 2019, Human gene therapy methods.

[77]  Hao Zhu,et al.  Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA. , 2017, Angewandte Chemie.

[78]  Eunji Kim,et al.  In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni , 2017, Nature Communications.

[79]  R. Hardison,et al.  Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells , 2018, Science.

[80]  A. Bradley,et al.  Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements , 2018, Nature Biotechnology.

[81]  M. Terns,et al.  CRISPR-Based Technologies: Impact of RNA-Targeting Systems. , 2018, Molecular cell.

[82]  Martha L. Bulyk,et al.  Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch , 2018, Cell.

[83]  Bin Zhang,et al.  CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia. , 2019, The New England journal of medicine.

[84]  S. S. St Martin,et al.  Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[85]  Xiaoshu Xu,et al.  A CRISPR-dCas Toolbox for Genetic Engineering and Synthetic Biology. , 2019, Journal of molecular biology.

[86]  M. Modarressi,et al.  Genetic disruption of the KLF1 gene to overexpress the γ‐globin gene using the CRISPR/Cas9 system , 2016, The journal of gene medicine.

[87]  X. Yang,et al.  Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing in Bone-Marrow-Derived CD34+ Hematopoietic Stem and Progenitor Cells , 2017, Molecular therapy. Methods & clinical development.

[88]  Haoyi Wang,et al.  Delivery of CRISPR-Cas9 into Mouse Zygotes by Electroporation. , 2018, Methods in molecular biology.

[89]  Laura J. Norton,et al.  Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding , 2018, Nature Genetics.

[90]  Dana Carroll,et al.  Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells , 2016, Science Translational Medicine.

[91]  M. Porteus,et al.  Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus. , 2018, Blood.

[92]  Kaihong Zhou,et al.  Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing. , 2018, Journal of the American Chemical Society.

[93]  Luke A. Gilbert,et al.  Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.

[94]  Daesik Kim,et al.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.

[95]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[96]  Anirvan Ghosh,et al.  Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes , 2017, Nature Biotechnology.

[97]  G. Babcock,et al.  Mouse embryonic stem cells, but not somatic cells, predominantly use homologous recombination to repair double-strand DNA breaks. , 2010, Stem cells and development.

[98]  Xiangdong Gao,et al.  Potent Protein Delivery into Mammalian Cells via a Supercharged Polypeptide. , 2018, Journal of the American Chemical Society.

[99]  P. Shieh.  Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy , 2018, Neurotherapeutics.

[100]  Gregory McAllister,et al.  p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells , 2018, Nature Medicine.

[101]  D. Shriner,et al.  Human Germline Genome Editing. , 2017, American journal of human genetics.

[102]  John M. Shelton,et al.  Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy , 2018, Science.

[103]  Renzhi Han,et al.  CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[104]  Jennifer A. Doudna,et al.  Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery , 2017, Nucleic acids research.

[105]  J. Xie,et al.  Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9 , 2018, Front. Immunol..

[106]  Nicole M. Gaudelli,et al.  Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage , 2017, Nature.

[107]  E. Olson,et al.  CRISPR Correction of Duchenne Muscular Dystrophy. , 2019, Annual review of medicine.

[108]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[109]  J. Keith Joung,et al.  Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo , 2014, Nature Biotechnology.

[110]  Jussi Taipale,et al.  CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response , 2018, Nature Medicine.

[111]  Aymeric Duclert,et al.  Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. , 2015, Cancer research.

[112]  Elo Leung,et al.  A TALE nuclease architecture for efficient genome editing , 2011, Nature Biotechnology.

[113]  Zachary Glass,et al.  Nanoparticles for CRISPR–Cas9 delivery , 2017, Nature Biomedical Engineering.